


Pulmonary Embolism Diagnostics Market: Size, Trends & Forecasts (2017-2021)

April 2017

PULMONARY EMBOLISM



Daedal Research

Global Pulmonary Embolism Diagnostics Market Report

Scope of the Report

The report titled "Global Pulmonary Embolism Diagnostic Market: Size, Trends & Forecasts (2017-2021)", provides an in-depth analysis of the developed region pulmonary embolism diagnostic market by value, by volume (number of patients), by segments, etc.

The report provides an analysis of the developed regions such as Canada, Australia and Europe on the basis of diagnostics penetration and the regions such as the US with an addressable market opportunity for the diagnostics penetration.

The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global pulmonary thromboembolism diagnostics market has also been forecasted for the period 2017-2021, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

The competition in the pulmonary thromboembolism diagnostic market, especially V/Q scan is dominated by one big player at global level, Cyclopharm and at regional level, in the US, the competition is dominated by Lantheus Holdings, Inc. (Xe-133).

Further, key players of the global pulmonary thromboembolism diagnostic market Cyclopharm, Philips, Siemens and Jubilant LifeSciences Limited are also profiled with their financial information and respective business strategies.

Country Coverage

Developed Regions (Canada, Europe, Australia and Parts of Asia)

The US

Company Coverage

Cyclopharm

Jubilant LifeSciences Limited

Philips

Siemens

Global Pulmonary Embolism Diagnostics Market Report

Executive Summary

Venous Thromboembolism (VTE) is a type of blood clot that starts in the vein. Most commonly VTE starts in the legs of the patient, however, it could occur in any other part of the body also. There are two types of VTE: Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE).

The pulmonary embolism generally occurs due to DVTs or pelvic vein thrombosis.

Pulmonary embolism is a condition where the clot that is formed deep into the veins of the patient legs (or in any other body part) breaks off and travels through the bloodstream to the lungs. The clot has a tendency to block a blood vessel in the lungs and hence damage them.

Pulmonary embolism is not a disease rather it is a complication of underlying VTE. There are several risk factors for pulmonary embolism such as cancer, obesity, sedentary lifestyle, age factor, major surgery, genetic blood clotting disorder or fracture of the hip or leg, etc. The onset of pulmonary embolism is depicted by shortness of breath, sudden chest pain and coughing blood. These symptoms are then followed by other symptoms such as flank pain, wheezing, cardiac murmur, etc.


There are different types of tests done to detect pulmonary embolism, however, Computed Tomography Pulmonary Angiogram (CTPA) is the gold standard for detecting pulmonary embolism. Another alternative test done to detect pulmonary embolism is Ventilation-Perfusion (V/Q) Scanning.

Since prevention is better than cure, a healthy lifestyle is most commonly prescribed to prevent pulmonary embolism. However, pulmonary embolism is managed majorly through intake of anticoagulants, thrombolytics, vena cava filter and compression stockings.

The global pulmonary embolism diagnostics market is anticipated to increase at a significant CAGR during the years 2017-2021. The pulmonary embolism diagnostic market is expected to increase due to growth in number of cancer patients, aging population, increase in per-capita healthcare expenditure, etc. Yet the market faces some challenges such as, prohibition of Technegas (an agent of V/Q Scan) in the US and introduction of Novel Oral anticoagulants.


Global Pulmonary Embolism Diagnostics Market Overview

Developed Region Pulmonary Embolism Diagnostic Market by Value; 2015-2021 (US\$ Million)




The developed region pulmonary embolism diagnostics market by value is estimated to rise to US\$....million by 2021 from US\$...million in 2015. The developed region pulmonary embolism market by number of patients is likely to increase to ...million patients by 2021 from ...million patients in 2015. The developed region pulmonary embolism diagnostics market could be segregated into ... and ...The larger segment was ... with ...% share in 2015.

Developed Region Pulmonary Embolism Diagnostic Market by Number of Patients; 2015-2021 (Million)




Developed Region Pulmonary Embolism Diagnostics Market by Tests; 2015 (Percentage, %)




Global Pulmonary Embolism Diagnostics Market Segments Overview

Developed Region Pulmonary Embolism V/Q Scan Diagnostic Market by Value; 2015-2021 (US\$ Million)



Developed Region Pulmonary Embolism CTPA Diagnostic Market by Value; 2015-2021 (US\$ Million)



The developed region pulmonary embolism V/Q scan diagnostic market is anticipated to reach US\$...million by 2021 from US\$...million in 2015. The developed region pulmonary embolism CTPA market by value is expected to increase to US\$...million by 2021 from US\$.....million in 2015.

Pulmonary Embolism Diagnostic Market: Regional Overview

Table 1: The US Pulmonary Embolism Diagnostic Technegas Addressable Market; 2015

Pulmonary Embolism cases per annum (Million) in the region	xx
Percentage of pulmonary embolism cases to be diagnosed using V/Q Scan	xx
Percentage of pulmonary embolism cases to be diagnosed using CTPA	xx
Addressable market for pulmonary embolism in the region by number of patients for V/Q Scans	xx
Average selling price	xx
Revenue per annum from V/Q scans	xx
<i>Source: Company Reports, Daedal Research</i>	